MYCN and neuroblastoma: To delineate the immune composition of NB tumors, we performed IHC on 18 human patient samples {n = 5, early-stage NB; n = 7, non-MYCN amplified (MYCN-NA) late-stage NB, n = 6, MYCN amplified (MYCN-A) late-stage NB} collected under IRB protocol (071729) (Supplementary Table S1).